MT SB422

Prohibits health insurers in Montana's individual and group markets from requiring patients with advanced or metastatic cancer to fail on a different drug first (step therapy) before covering FDA-approved prescription drugs that follow National Comprehensive Cancer Network guidelines

Applies to drugs that are FDA-approved, supported by peer-reviewed evidence-based literature, and consistent with best practices for treating advanced/metastatic cancer

Defines "advanced or metastatic cancer" as cancer that has spread from the primary site to nearby tissues, lymph nodes, or other body areas, or has progressed beyond early stages and is considered terminal

Amends state employee benefit plan requirements, health maintenance organization statutes, and self-funded multiple employer welfare arrangement regulations to incorporate these new cancer treatment coverage provisions

Removes the previous definition of "associated condition" (symptoms/side effects of cancer or treatment) and adds a definition of "terminal cancer" as cancer that cannot be cured and is expected to lead to death